Back
Morguard North American Residential REIT 10K Form
Buy
65
MNARF
Morguard North American Residential REIT
Last Price:
$12.18
Seasonality Move:
-2.14%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive MNARF News And Ratings
See the #1 stock for the next 7 days that we like better than MNARF
MNARF Financial Statistics
Sales & Book Value
| Annual Sales: | $251.2M |
|---|---|
| Cash Flow: | $13.7M |
| Price / Cash Flow: | 10.29 |
| Annual Sales: | $27.44 |
| Price / Book: | 0.46 |
Profitability
| EPS (TTM): | 1.58660 |
|---|---|
| Net Income (TTM): | $88.1M |
| Gross Margin: | $118.2M |
| Return on Equity: | 5.9% |
| Return on Assets: | 2.71% |
Morguard North American Residential REIT Earnings Forecast
Key Morguard North American Residential REIT Financial Ratios
-
The Gross Profit Margin over the past 14 years for MNARF is 47.04%.
-
The Selling, General & Administrative Expenses for MNARF have been equal to 0.00% of Gross Profit Margin.
-
The Interest Expense is 69.60% of Operating Income.
-
The Net Earning history of MNARF is 28.88% of Total Revenues.
-
Per Share Earnings over the last 14 years have been positive in 3 years.
Morguard North American Residential REIT Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | OTCM |
|---|---|
| Industry: | Residential REITs |
| Sector: | Real Estate |
| Current Symbol: | MNARF |
| Website: | morguard.com/investor-relations/morguard-north-american-residential-reit |
Debt
| Debt-to-Equity Ratio: | 0.9 |
|---|---|
| Current Ratio: | 0.82 |
| Quick Ratio: | 0.37 |
Price-to-Earnings
| Trailing P/E Ratio: | 9.72 |
|---|---|
| Forward P/E Ratio: | 0 |
MNARF Technical Analysis vs Fundamental Analysis
Buy
65
Morguard North American Residential REIT (MNARF)
is a Buy
Is Morguard North American Residential REIT a Buy or a Sell?
-
Morguard North American Residential REIT stock is rated a BuyThe current Morguard North American Residential REIT [MNARF] share price is $12.75. The Score for MNARF is 65, which is 30% above its historic median score of 50, and infers lower risk than normal.